Insights: Events The Future of Inducement Claims in the Hatch-Waxman Context: Reconciling the Demarcation Between Describing and Infringing Use and Encouraging That Use in a Label

17th Annual Paragraph IV Disputes Conference

Tuesday, April 26, 2022

  • Analyzing whether a skinny label alone is enough to preclude induced infringement allegations
  • Reviewing the implications of recent decisions for induced infringement
    • Anticipating the impact of recent decisions on claim drafting and the availability of generic drugs
  • Devising strategic considerations of label language for inducement infringement
    • What considerations should patent owners keep in mind when labeling drugs?
  • Reviewing the approval of generic drug labeling
    • On what basis will FDA determine the scope of an appropriate carve-out?
    • Must FDA review the patent to ensure the only information carved out is covered by the patent?
    • Is the interpretation of the patent claims subject only to a jury’s interpretation?
  • Assessing the flurry of follow-on cases in the courts

Event Details

Tuesday, April 26, 2022


In-Person and Livestream
New York, New York

11:15 a.m. - 12:15 p.m.

Latest Thinking

View more Insights
Insights Center
close
Loading...
If you would like to receive related insights and information from Kilpatrick Townsend, please provide your contact details by filling out the form and clicking “Agree.” If you would like to access the PDF only, please click “Download Only.”